Drugs policy advisor under fire over links to pharmaceutical company

 

A senior health advisor is facing criticism for his links to a company involved in a million pound drug trial.

Professor John Strang, an architect of drugs policy for more than a decade, is chief clinical investigator in a publicly funded heroin-antidote trial on thousands of prisoners.

Questions over Professor Strang's links comes just months after he was criticised for failing to disclose ties to drug companies when applying for a government project.

The latest case has caused outrage among campaigners who say drug addiction policies have for too long been open to abuse from vested interests. The issue will be discussed by the Inter Ministerial Group on Drugs this week, The Independent has learnt. 

Professor Strang has confirmed receipt of research grants, consultancy payments and travel expenses from several pharmaceutical companies who make medicines to treat addictions including Martindale Pharma and Cardinal Health.

Martindale, owned by Cardinal Health until May 2010, was the manufacturer chosen by the researchers in 2009 to supply pre-filled syringes of the drug Naloxone being used in the pilot study which could eventually involve 56,000 prisoners in England. The study, called N-ALIVE, hopes to reduce overdose deaths in the first month after release from prison.

The relationship between Professor Strang, director of the National Addiction Centre at King’s College London, with Martindale Pharma has publicly emerged - three years after the £1m grant trial was approved by the Indian Council of Medical Research.

Martindale, owned by Cardinal Health until May 2010, was the manufacturer chosen by the researchers in 2009 to supply pre-filled syringes of the drug Naloxone being used in the pilot study which could eventually involve 56,000 prisoners in England. The study, called N-ALIVE, hopes to reduce overdose deaths in the first month after release from prison.

He did not formally declare any conflicts of interest to the ICMR during the application process - which the ICMR says complies with current rules.

Professor Parmar, senior ICMR board member, director of the ICMR clinical trials unit and head of N-ALIVE, said: “Professor Strang told me about his links to drug companies but it was not material to our decision to use Martindale so I decided there was no need to further dissect these links… We followed normal processes but I agree that you have raised a fair point that warrants broader discussion.” (must keep)

No-one else was involved in this decision, which is again within current rules. Researchers must formally declare interests only when submitting a paper for peer review – after the study is complete.

The Ministry of Justice and Department of Health approved the prison-study but claim it was not their role to check for conflicts of interest.  A letter was sent to prisoner governors and NHS bosses about N-ALIVE from government officials and the three researchers written on MoJ and DH headed notepaper. Critics say the government ought to have known about Professor Strang’s link with the drug company which should have been declared in this letter.

The ICMR N-ALIVE webpage has recently added some limited declarations of interest to Professor Strang’s profile but no drug companies are mentioned by name. The change was made as health officials were alerted to the “potential embarrassment” by a drug policy campaigner and after a freedom of information request by Kathy Gyngell, research fellow at Centre for Policy Studies.

MPs and drug experts last night called for urgent action to ensure external government advisors and arms length bodies, often instrumental in shaping government policies, are forced to declare all potential conflicts of interests.

It is the second time in a year that Professor Strang’s pharmaceutical links have been questioned. In July, The Independent revealed how Professor Strang had failed to disclose links with drug companies that sell tranquilisers such as Valium before conducting a DH review into the same drugs. His report is guiding government policy in this area.

Professor Strang’s presentation advocating Naloxone is on the United Nations Office of Drug Control website. His declaration of interests includes several drug companies but there is no mention of Naloxone manufacturer Martindale.

Jim Dobbin, chair of the All Party Group on Involuntary Tranquilliser Addiction, said: “All advisors or researchers who may influence government policy must declare any links with organisations or companies that could benefit from Government policy, so that there is complete transparency. The government must urgently review what information it explicitly asks influential external advisors like Professor Strang so that every link with every company is known.”

Eric Ollerenshaw, Tory MP who campaigns for better addiction services said: “I am not a medical expert, so I need to know that so-called independent advisors being relied upon to make drug policies are actually independent of drug companies.”

The £984,000 grant for the N-ALIVE pilot study involves 5,600 prisoners. The main study, which will cost at least £5m, will test whether giving known heroin users pre-filled syringes of the antidote upon release reduces deaths in the first four weeks by 28 per cent. Success will depend on the overdose taking place in the presence of others who are able, and willing, to inject the antidote within 20-30 minutes.

But drug experts are still divided about safety and the principle of take-home Naloxone to treat heroin overdoses.

It is routinely carried in ambulances and Professor Strang, a staunch supporter for more than 10 years, claims the drug could save hundreds of lives if routinely carried by heroin-users. It has been rolled-out in Scotland, despite a lack of robust clinical evidence; there are ongoing concerns about potential side effects especially when administered without medical supervision.

Critics argue that limited resources should be targeted at longer-term solutions, including helping addicts to detox in prison and providing addiction support upon release.

Dr Alex Wodak, former president of the International Harm Reduction Association, said the study would determine whether Naloxone was safe and cost effective. “Naloxone is very interesting but the evidence is still weak… Whether money is better spent on research or on proven interventions is always a real dilemma - in my view we should do both.”

Kathy Gyngell, a vocal critic of drug-focused addiction policy, said: “That the ICMR can act as judge and jury over declaration of interests is not just slack; it is unacceptable. The ICMR will have little credibility and less respect if it does not now request a full declaration of Professor Strang's relationship with the Pharmaceutical companies he done research for and whose products he advocates… Given that Naloxone is a highly controversial intervention… he should be subject to immediate and independent investigation.”

Martindale said: “Martindale Pharma has not had any contract with Professor Strang and has not provided any financial support to Professor Strang for N-Alive or any other project,” but would not clarify further. Professor Strang declined to comment.

* From tragedy to travesty: Drugs tested on survivors of Bhopal
* Without consent: how drugs companies exploit Indian 'guinea pigs'
* Leading article: Drugs firms must not prey on poverty

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
Have you tried new the Independent Digital Edition apps?
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Ashdown Group: Application Support Analyst- (Customer Support) - £29,000

£29000 per annum: Ashdown Group: Application Support Analyst- (Customer Suppor...

Recruitment Genius: Laser Games Supervisor

£14500 - £15000 per annum: Recruitment Genius: This is an exciting opportunity...

Recruitment Genius: PPC Executive / Manager

£22000 - £28000 per annum: Recruitment Genius: A PPC Executive/Manager is requ...

Ashdown Group: Service Delivery Manager - Retail / FMCG / WMS Operations

£55000 per annum: Ashdown Group: Service Delivery Manager - Retail / FMCG / WM...

Day In a Page

Isis hostage crisis: Militant group stands strong as its numerous enemies fail to find a common plan to defeat it

Isis stands strong as its numerous enemies fail to find a common plan to defeat it

The jihadis are being squeezed militarily and economically, but there is no sign of an implosion, says Patrick Cockburn
Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action

Virtual reality: Seeing is believing

Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
Homeless Veterans appeal: MP says Coalition ‘not doing enough’

Homeless Veterans appeal

MP says Coalition ‘not doing enough’ to help
Larry David, Steve Coogan and other comedians share stories of depression in new documentary

Comedians share stories of depression

The director of the new documentary, Kevin Pollak, tells Jessica Barrett how he got them to talk
Has The Archers lost the plot with it's spicy storylines?

Has The Archers lost the plot?

A growing number of listeners are voicing their discontent over the rural soap's spicy storylines; so loudly that even the BBC's director-general seems worried, says Simon Kelner
English Heritage adds 14 post-war office buildings to its protected lists

14 office buildings added to protected lists

Christopher Beanland explores the underrated appeal of these palaces of pen-pushing
Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

Scientists unearthed the cranial fragments from Manot Cave in West Galilee
World War Z author Max Brooks honours WW1's Harlem Hellfighters in new graphic novel

Max Brooks honours Harlem Hellfighters

The author talks about race, legacy and his Will Smith film option to Tim Walker
Why the league system no longer measures up

League system no longer measures up

Jon Coles, former head of standards at the Department of Education, used to be in charge of school performance rankings. He explains how he would reform the system
Valentine's Day cards: 5 best online card shops

Don't leave it to the petrol station: The best online card shops for Valentine's Day

Can't find a card you like on the high street? Try one of these sites for individual, personalised options, whatever your taste
Diego Costa: Devil in blue who upsets defences is a reminder of what Liverpool have lost

Devil in blue Costa is a reminder of what Liverpool have lost

The Reds are desperately missing Luis Suarez, says Ian Herbert
Ashley Giles: 'I'll watch England – but not as a fan'

Ashley Giles: 'I'll watch England – but not as a fan'

Former one-day coach says he will ‘observe’ their World Cup games – but ‘won’t be jumping up and down’
Greece elections: In times like these, the EU has far more dangerous adversaries than Syriza

Greece elections

In times like these, the EU has far more dangerous adversaries than Syriza, says Patrick Cockburn
Holocaust Memorial Day: Nazi victims remembered as spectre of prejudice reappears

Holocaust Memorial Day

Nazi victims remembered as spectre of prejudice reappears over Europe
Fortitude and the Arctic attraction: Our fascination with the last great wilderness

Magnetic north

The Arctic has always exerted a pull, from Greek myth to new thriller Fortitude. Gerard Gilbert considers what's behind our fascination with the last great wilderness